Literature DB >> 27776908

The High Value Healthcare Collaborative: Observational Analyses of Care Episodes for Hip and Knee Arthroplasty Surgery.

William B Weeks1, William J Schoellkopf2, Lyle S Sorensen3, Andrew L Masica4, Robert E Nesse5, James N Weinstein6.   

Abstract

BACKGROUND: Broader use of value-based reimbursement models will require providers to transparently demonstrate health care value. We sought to determine and report cost and quality data for episodes of hip and knee arthroplasty surgery among 13 members of the High Value Healthcare Collaborative (HVHC), a consortium of health care systems interested in improving health care value.
METHODS: We conducted a retrospective, cross-sectional observational cohort study of 30-day episodes of care for hip and knee arthroplasty in fee-for-service Medicare beneficiaries aged 65 or older who had hip or knee osteoarthritis and used 1 of 13 HVHC member systems for uncomplicated primary hip arthroplasty (N = 8853) or knee arthroplasty (N = 16,434), respectively, in 2012 or 2013. At the system level, we calculated: per-capita utilization rates; postoperative complication rates; standardized total, acute, and postacute care Medicare expenditures for 30-day episodes of care; and the modeled impact of reducing episode expenditures or per-capita utilization rates.
RESULTS: Adjusted per-capita utilization rates varied across HVHC systems and postacute care reimbursements varied more than 3-fold for both types of arthroplasty in both years. Regression analysis confirmed that total episode and postacute care reimbursements significantly differed across HVHC members after considering patient demographic differences. Potential Medicare cost savings were greatest for knee arthroplasty surgery and when lower total reimbursement targets were achieved.
CONCLUSION: The substantial variation that we found offers opportunities for learning and collaboration to collectively improve outcomes, reduce costs, and enhance value. Ceteris paribus, reducing per-episode reimbursements would achieve greater Medicare cost savings than reducing per-capita rates.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medicare; episodes of care; health care costs; joint arthroplasty; postacute care

Mesh:

Year:  2016        PMID: 27776908     DOI: 10.1016/j.arth.2016.09.009

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  5 in total

1.  The Impact Of Decision Aids On Adults Considering Hip Or Knee Surgery.

Authors:  Vanessa B Hurley; Hector P Rodriguez; Stephen Kearing; Yue Wang; Ming D Leung; Stephen M Shortell
Journal:  Health Aff (Millwood)       Date:  2020-01       Impact factor: 6.301

2.  Decision Aid Implementation and Patients' Preferences for Hip and Knee Osteoarthritis Treatment: Insights from the High Value Healthcare Collaborative.

Authors:  Vanessa B Hurley; Yue Wang; Hector P Rodriguez; Stephen M Shortell; Stephen Kearing; Lucy A Savitz
Journal:  Patient Prefer Adherence       Date:  2020-01-06       Impact factor: 2.711

3.  Episode-of-Care Characteristics and Costs for Hip and Knee Replacement Surgery in Hospitals Belonging to the High Value Healthcare Collaborative Compared With Similar Hospitals in the Same Health Care Markets.

Authors:  William B Weeks; William J Schoellkopf; David J Ballard; Gary S Kaplan; Brent James; James N Weinstein
Journal:  Med Care       Date:  2017-06       Impact factor: 2.983

4.  Cost Determinants of Continuum-Care Episodes for Hip Fracture.

Authors:  Davide Golinelli; Erik Boetto; Antonio Mazzotti; Simona Rosa; Paola Rucci; Elena Berti; Cristina Ugolini; Maria Pia Fantini
Journal:  Health Serv Insights       Date:  2021-02-16

5.  Non-compliance with clinical guidelines increases the risk of complications after primary total hip and knee joint replacement surgery.

Authors:  Helen Mary Badge; Tim Churches; Justine M Naylor; Wei Xuan; Elizabeth Armstrong; Leeanne Gray; John Fletcher; Iain Gosbell; Christine Lin; Ian A Harris
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.